NIH SBIR/STTR Program: Rare Skin Disease, Gene Therapy & Dermatology Innovation is sponsored by National Institutes of Health (NIH). This opportunity supports mission-aligned projects and measurable outcomes.

NIH Highlighted Topic: Rare Skin Disease, Gene Therapy & Dermatology Innovation SBIR Funding Opportunity — BW&CO NIH Highlighted Topic: Advancing Research into the Cause and Treatment of Rare Skin Diseases Below is a brief summary. Please check the full solicitation before applying (link in resources section).

The National Institutes of Health (NIH) is encouraging innovative research proposals focused on advancing the understanding, diagnosis, and treatment of rare skin diseases through multidisciplinary basic, translational, and clinical research.

This highlighted topic supports projects aimed at uncovering disease mechanisms, identifying therapeutic targets, improving diagnostics, and accelerating the development of novel treatments for rare dermatological conditions that currently lack effective therapies.

NIH is particularly interested in projects investigating the genetic, molecular, cellular, and environmental factors contributing to rare skin diseases, many of which present in childhood and have limited or no FDA-approved treatment options.

Companies developing dermatology therapeutics, gene therapies, AI-enabled diagnostics, biomarker technologies, organoid models, computational biology platforms, precision medicine systems, or regenerative medicine solutions may be strong candidates for funding.

Areas of interest include genetic studies, biomarker discovery, environmental exposure research, disease modeling, organoids and organ-on-chip systems, drug repurposing, gene editing, cell therapies, revertant mosaicism research, and therapeutics targeting shared molecular disease mechanisms across multiple rare skin disorders.

NIH is also encouraging projects using New Approach Methodologies (NAMs), computational modeling, and translational platform technologies that can accelerate drug discovery and therapeutic development.

Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.

This highlighted topic is supported by multiple NIH Institutes and Offices including the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Advancing Translational Sciences (NCATS), National Institute of Environmental Health Sciences (NIEHS), and the Office of Research on Women’s Health (ORWH), all of which are seeking transformative innovations that improve rare skin disease diagnosis, therapeutics, translational research, and patient outcomes.

How much funding would I receive? Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits.

Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II. What could I use the funding for? Funding may support the research, development, validation, and commercialization of therapeutics, diagnostics, computational tools, disease models, and translational research platforms related to rare skin diseases.

Eligible activities may include: Gene therapy and gene editing technologies for rare skin diseases AI and machine learning platforms for dermatology diagnostics and biomarker discovery Cell therapy and regenerative medicine approaches Organoid, 3D tissue culture, and organ-on-chip disease modeling systems Computational biology and precision medicine platforms Biomarker discovery and disease progression monitoring technologies Drug repurposing and therapeutic screening systems Molecular and cellular pathway analysis tools Environmental exposure and exposome research technologies Translational platform technologies applicable across multiple rare diseases Basket trial infrastructure and shared molecular etiology therapeutic development Dermatology imaging and digital pathology systems Personalized medicine and genomic diagnostic platforms High-throughput drug screening and toxicology testing systems Autoimmune-associated skin disease therapeutic technologies Revertant mosaicism and disease reversal research platforms Prototype development, translational studies, and clinical validation research Commercialization planning, regulatory preparation, and manufacturing scale-up activities Funding may also support personnel, laboratory testing, software engineering, AI model development, cloud infrastructure, genomic sequencing, bioinformatics analysis, preclinical studies, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable dermatology or biotechnology solution aligned with NIH priorities.

Are there any additional benefits I would receive? Beyond the formal funding award, awardees gain several strategic advantages: Government Validation and Credibility: Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

Enhanced Visibility and Market Recognition: Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities. Access to the Federal Innovation Ecosystem: Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

Stronger Commercial and Exit Potential: By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment. What is the timeline to apply and when would I receive funding? Applications are accepted each year on January 5th, April 5th, and September 5th.

Funding is received approximately 9 months after submission. Where does this funding come from? Funding comes from the U.S. Department of Health and Human Services , with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.

2% for SBIR, 0. 45% for STTR) to support small business innovation. Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that: Are organized for profit with a U.S. place of business. Have ≤ 500 employees including affiliates. Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win? Projects that demonstrate: A clear unmet medical or public-health need , Strong scientific rationale and feasibility , High commercialization potential , supported by a realistic market and regulatory strategy, and Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption. Are there any restrictions I should know about? Companies must complete multiple federal registrations ( SAM.

gov , Grants. gov , eRA Commons, SBA Company Registry) before applying. Foreign entities are not eligible .

Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation. How long will it take me to prepare an application?

For a first-time applicant , preparing a competitive submission will likely take 120–200 hours in total.

Our team specializes in complex federal R&D proposals and can: Triple your likelihood of success through proven strategy and insider-aligned proposal development Reduce your time spent on the proposal by 50–80% , letting your team focus on technology and operations Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth. Review solicitation here.

Biotech Medtech Healthtech NIH Highlighted Topic: Advancing Toward a Cure for Acquired Neuropathy NIH Highlighted Topic: Advancing “Science of Science” Research to Understand and Strengthen the Biomedical Research Ecosystem